(RTTNews) - Michelin (ML.PA) said on Wednesday, that first-quarter 2026 tire volumes are expected to decline in the low-to-mid single-digit range as weaker original equipment demand continues across major markets, while replacement demand remains broadly stable.
(RTTNews) - Michelin (ML.PA) said on Wednesday, that first-quarter 2026 tire volumes are expected to decline in the low-to-mid single-digit range as weaker original equipment demand continues across major markets, while replacement demand remains broadly stable.
Ecuador’s President Daniel Noboa says he would welcome US troops to help address his country’s “security crisis,” as long as they follow the lead of local armed forces. In an interview with Bloomberg’s Annmarie Hordern in Guayaquil, Noboa says the US is already offering support and that he is open to deeper involvement from President Donald Trump’s administration. (Source: Bloomberg)
Ecuador’s President Daniel Noboa says he would welcome US troops to help address his country’s “security crisis,” as long as they follow the lead of local armed forces. In an interview with Bloomberg’s Annmarie Hordern in Guayaquil, Noboa says the US is already offering support and that he is open to deeper involvement from President Donald Trump’s administration. (Source: Bloomberg)
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. The stock market gains carried through Wednesday's session as equities rebounded on news that the U.S. and Iran agreed to a two-week ceasefire predicated on the reopening of the Strait of Hormuz. After nearly touching $113 per b...
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. The stock market gains carried through Wednesday's session as equities rebounded on news that the U.S. and Iran agreed to a two-week ceasefire predicated on the reopening of the Strait of Hormuz. After nearly touching $113 per barrel at one point on Tuesday, oil prices plummeted. West Texas Intermediate crude dropped more than 15% to the mid-$90s. WTI hasn't seen those levels for about two weeks. Bond yields followed oil prices lower, with the 10-year Treasury yield dropping to around 4.28%. Every sector was positive Wednesday, except for energy. Some of the biggest gains were in the most cyclical and interest rate-sensitive parts of the market, like industrials, consumer discretionary, materials, and financials. The Magnificent Seven tech stocks and AI-related names powered the market higher, too. Late in the session, the S & P 500 was up 2.5%, and the Nasdaq was up 3%. As Jim Cramer said on the Morning Meeting, the price action Wednesday is exactly why we don't try to time the market . Getting out last week at the lows since the war started on Feb. 28, you would have missed the move higher since then, especially the rip higher on Wednesday. It's nearly impossible to be right on both sides of such a trade. Meta Platforms shares surged after the company on Wednesday announced a new AI model. It's called Muse Spark, and Meta said it is the first of its Muse family of models developed by its Superintelligence Labs team. Muse Spark was made available Wednesday at meta.ai and in the Meta AI app. While Meta's advertising business and engagement time on its social media platforms have benefited from leveraging AI, the company's attempts thus far at developing a popular model have been unsuccessful. Llama was an underperformer — but with Muse Spark, the company believes it will be more competitive with A...
The U.S. Food and Drug Administration (FDA) has warned Medline ( MDLN ) that the agency will be compelled to take regulatory action regarding violations related to the production of its NAMIC Angiographic Control Syringes, indicated for certain heart procedures. In a letter dated Mar. 25 addressed to Medline ( MDLN ) CEO Jim Boyle, the FDA pointed out that the company has yet to take adequate meas...
The U.S. Food and Drug Administration (FDA) has warned Medline ( MDLN ) that the agency will be compelled to take regulatory action regarding violations related to the production of its NAMIC Angiographic Control Syringes, indicated for certain heart procedures. In a letter dated Mar. 25 addressed to Medline ( MDLN ) CEO Jim Boyle, the FDA pointed out that the company has yet to take adequate measures to address the violations identified during an inspection at its manufacturing site in Glens Falls, New York, in December. The inspection came as complaints "regarding disconnection from manifolds” in NAMIC devices increased in June 2023 due to a defect Medline ( MDLN ) attributed to the presence of excess silicone. In a response sent to the regulator a year later, the company determined that the risk was low, a finding that the FDA said was not in line “with your design failure modes and effectiveness analysis." Despite 221 complaints and 177 safety reports, “your firm’s corrective actions only included scrapping devices in inventory and increasing the cleaning frequency of machine to prevent excess silicone from migrating to the luer connector,” the agency said. With Medline’s ( MDLN ) solutions failing to address the issue, complaints continued to rise, and the company pledged to remove the devices from the market in February. The FDA also noted that the company has failed to establish and follow standards related to proper cleaning and maintenance of equipment at the production facility. The agency required Medline ( MDLN ) to respond to the letter within 15 business days and said that if the company fails to address the matter adequately, it will face regulatory actions, including financial penalties. More on Medline Inc. Medline: A Lack Of Compelling Risk-Reward Makes Me Cautious Medline Inc. (MDLN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Medline Inc. (MDLN) Q4 2025 Earnings Call Transcript Medline prices $3B secondary offering at...
Shares of Axon Enterprise (NASDAQ: AXON) , the maker of TASER electrical weapons, body cameras, and related software, were moving higher today, one day after the stock plunged 10%. There was no clear cause for yesterday's decline. It possibly stemmed from events at the company's Axon Week annual conference, being held this week, or a report about a legal dispute over its new planned headquarters, ...
Shares of Axon Enterprise (NASDAQ: AXON) , the maker of TASER electrical weapons, body cameras, and related software, were moving higher today, one day after the stock plunged 10%. There was no clear cause for yesterday's decline. It possibly stemmed from events at the company's Axon Week annual conference, being held this week, or a report about a legal dispute over its new planned headquarters, which will begin a court hearing on Friday. However, Axon jumped as much 10.7% today. The gains came in part in response to the ceasefire in Iran, which lifted stocks broadly, but also as several supportive analyst notes came out in response to its conference. Continue reading